Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Diabetes Mellitus, Type 2 3Pancreatic Neoplasms 2Pulmonary Disease, Chronic Obstructive 1Neoplasms 1Lung Neoplasms 1Disease 1

Interventions

Surveys and Questionnaires 86Blood Specimen Collection 59Interviews as Topic 28Observation 15Data Collection 15Radiotherapy 13Drug Therapy 12Watchful Waiting 11Magnetic Resonance Spectroscopy 11Hematologic Tests 11Exercise 11Quality of Life 9Biopsy 8Specimen Handling 7Therapeutics 6Restraint, Physical 6Magnetic Resonance Imaging 6Focus Groups 6pembrolizumab 5Standard of Care 5Rivaroxaban 5Phlebotomy 5Nivolumab 5Lapatinib 5Immune Checkpoint Inhibitors 5Antineoplastic Agents 5atezolizumab 4apixaban 4Trastuzumab 4Patient Reported Outcome Measures 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Neoplasms × Sulfonylurea Compounds × Clear all
NCT07628556 2026-06-05

Antidiabetic Medications and Risk of Cancer

University of Pecs

Completed
74,799 enrolled

Diabetes Mellitus, Type 2, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡